Choice of Systemic Drugs for the Management of Moderate-to-severe Psoriasis: A Cross-country Comparison Based on National Health Insurance Data

Authors

  • Emilie Sbidian Department of Dermatology, Hôpital Henri-Mondor, 51, av du Maréchal de Lattre de Tassigny, FR-94010 Créteil Cedex, France
  • Myriam Mezzarobba
  • Jason Shourick
  • Cécile Billionnet
  • Joël Coste
  • Alain Weill
  • Jérémie Rudant
  • Olivier Chosidow
  • Loes Hollestein
  • Tamar E.C. Nijsten

DOI:

https://doi.org/10.2340/00015555-3765

Keywords:

chronic disease, psoriasis, therapeutic, national health insurance

Abstract

Current management of moderate-to-severe psoriasis may be heterogeneous between European countries, probably due to differences in the organization of care. The aim of this study was to compare the utilization of systemic treatments for psoriasis between 2 coun­tries. All adults with psoriasis who were registered in the French (SNDS) and the Dutch (VEKTIS) national health insurance databases between 2012 and 2016 were eligible for inclusion. In France, 105,035 (15%) of 684,156 patients and, in the Netherlands, 37,405 (28.6%) of 130,822 patients received at least a systemic agent. In France, the proportion of patients treated with systemic agents was constant, while the type of drugs dispensed shifted from non-biological to biological agents. In the Netherlands, the first systemic treatment was methotrexate and, in France, acitretin. In France, the choice of the first biologic was much more variable than it was in the Netherlands, where a large proportion of patients were dispensed ustekinumab. This study highlights discrepancies between France and the Netherlands concerning the choice of first non-biologic agent and first biologic agent for patients with psoriasis. These discrepancies may be due to differences in the healthcare systems between the 2 countries.

Downloads

Download data is not yet available.

References

Parisi R, Symmons DPM, Griffiths CEM, Ashcroft DM, Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 2013; 133: 377-385.

https://doi.org/10.1038/jid.2012.339

Nijsten T, Looman CWN, Stern RS. Clinical severity of psoriasis in last 20 years of PUVA study. Arch Dermatol 2007; 143: 1113-1121.

https://doi.org/10.1001/archderm.143.9.1113

Mason AR, Mason J, Cork M, Dooley G, Hancock H. Topical treatments for chronic plaque psoriasis. Cochrane Database Syst Rev 2013: CD005028.

https://doi.org/10.1002/14651858.CD005028.pub3

Nast A, Gisondi P, Ormerod AD, Saiag P, Smith C, Spuls PI, et al. European S3-Guidelines on the systemic treatment of psoriasis vulgaris - Update 2015 - Short version - EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol 2015; 29: 2277-2294.

https://doi.org/10.1111/jdv.13354

Sbidian E, Chaimani A, Afach S, Doney L, Dressler C, Hua C, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev 2020; 1: CD011535.

https://doi.org/10.1002/14651858.CD011535.pub3

Nast A, Jacobs A, Rosumeck S, Werner RN. Efficacy and safety of systemic long-term treatments for moderate-to-severe psoriasis: a systematic review and meta-analysis. J Invest Dermatol 2015; 135: 2641-2648.

https://doi.org/10.1038/jid.2015.206

Nast A, Spuls PI, van der Kraaij G, Gisondi P, Paul C, Ormerod AD, et al. European S3-Guideline on the systemic treatment of psoriasis vulgaris - update apremilast and secukinumab - EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol 2017; 31: 1951-1963.

https://doi.org/10.1111/jdv.14454

Sbidian E, Giboin C, Bachelez H, Paul C, Beylot-Barry M, Dupuy A, et al. Factors associated with the choice of the first biologic in psoriasis: real life analysis from the Psobioteq cohort. J Eur Acad Dermatol Venereol 2017; 31: 2046-2054.

https://doi.org/10.1111/jdv.14406

Weill A, Dalichampt M, Raguideau F, Ricordeau P, Blotière P-O, Rudant J, et al. Low dose oestrogen combined oral contraception and risk of pulmonary embolism, stroke, and myocardial infarction in five million French women: cohort study. BMJ 2016; 353: i2002.

https://doi.org/10.1136/bmj.i2002

Tuppin P, Rudant J, Constantinou P, Gastaldi-Ménager C, Rachas A, de Roquefeuil L, et al. Value of a national administrative database to guide public decisions: from the système national d'information interrégimes de l'Assurance Maladie (SNIIRAM) to the système national des données de santé (SNDS) in France. Rev Epidemiol Sante Publique 2017; 65 Suppl 4: S149-S167.

https://doi.org/10.1016/j.respe.2017.05.004

Tuppin P, Drouin J, Mazza M, Weill A, Ricordeau P, Allemand H. Hospitalization admission rates for low-income subjects with full health insurance coverage in France. Eur J Public Health 2011; 21: 560-566.

https://doi.org/10.1093/eurpub/ckq108

Egeberg A, Mallbris L, Gislason GH, Skov L, Hansen PR. Risk of multiple sclerosis in patients with psoriasis: a Danish nationwide cohort study. J Invest Dermatol 2016; 136: 93-98.

https://doi.org/10.1038/JID.2015.350

Sbidian E, Mezzarobba M, Weill A, Coste J, Rudant J. Persistence of treatment with biologics for patients with psoriasis: a real-world analysis of 16 545 biologic-naïve patients from the French National Health Insurance database (SNIIRAM). Br J Dermatol 2019; 180: 86-93.

https://doi.org/10.1111/bjd.16809

Spuls PI, Tuut MK, van Everdingen JJE, de Rie MA, Werkgroep Psoriasis van de Nederlandse Vereniging voor Dermatologie en Venereologie. [The practice guideline 'Photo(chemo)therapy and systemic therapy in severe chronic plaque-psoriasis']. Ned Tijdschr Geneeskd 2004; 148: 2121-2125 (in Dutch).

Zweegers J, de Jong EMGJ, Nijsten TEC, de Bes J, te Booij M, Borgonjen RJ, et al. Summary of the Dutch S3-guidelines on the treatment of psoriasis 2011. Dutch Society of Dermatology and Venereology. Dermatol Online J 2014; 20: doj_21769.

https://doi.org/10.5070/D3203021769

van der Kraaij GE, Balak DMW, Busard CI, van Cranenburgh OD, Chung Y, Driessen RJB, et al. Highlights of the updated Dutch evidence- and consensus-based guideline on psoriasis 2017. Br J Dermatol 2019; 180: 31-42.

https://doi.org/10.1111/bjd.17198

Amatore F, Villani A-P, Tauber M, Viguier M, Guillot B, Psoriasis Research Group of the French Society of Dermatology (Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie). French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults. J Eur Acad Dermatol Venereol 2019; 33: 464-483.

https://doi.org/10.1111/jdv.15340

Loft N, Skov L, Bryld LE, Gislason G, Egeberg A. Treatment history of patients receiving biologic therapy for psoriasis - a Danish nationwide study. J Eur Acad Dermatol Venereol 2017; 31: e362-e363.

https://doi.org/10.1111/jdv.14156

Han JH, Lee JH, Han KD, Seo H-M, Bang CH, Park YM, et al. Epidemiology and medication trends in patients with psoriasis: a nationwide population-based cohort study from Korea. Acta Derm Venereol 2018; 98: 396-400.

https://doi.org/10.2340/00015555-2877

Wakkee M, Lugtenberg M, Spuls PI, de Jong EM, Thio HB, Westert GP, et al. Knowledge, attitudes and use of the guidelines for the treatment of moderate to severe plaque psoriasis among Dutch dermatologists. Br J Dermatol 2008; 159: 426-432.

https://doi.org/10.1111/j.1365-2133.2008.08692.x

Ighani A, Partridge ACR, Shear NH, Lynde C, Gulliver WP, Sibbald C, et al. Comparison of management guidelines for moderate-to-severe plaque psoriasis: a review of phototherapy, systemic therapies, and biologic agents. J Cutan Med Surg 2019; 23: 204-221.

https://doi.org/10.1177/1203475418814234

Smith CH, Jabbar-Lopez ZK, Yiu ZZ, Bale T, Burden AD, Coates LC, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. Br J Dermatol 2017; 177: 628-636.

https://doi.org/10.1111/bjd.15665

Dommasch ED, Lee MP, Joyce CJ, Garry EM, Gagne JJ. Drug utilization patterns and adherence in patients on systemic medications for the treatment of psoriasis: a retrospective, comparative cohort study. J Am Acad Dermatol 2018; 79: 1061-1068.e1.

https://doi.org/10.1016/j.jaad.2018.06.053

Chen X, Yang M, Cheng Y, Liu GJ, Zhang M. Narrow-band ultraviolet B phototherapy versus broad-band ultraviolet B or psoralen-ultraviolet A photochemotherapy for psoriasis. Cochrane Database Syst Rev 2013; CD009481.

https://doi.org/10.1002/14651858.CD009481.pub2

Additional Files

Published

2021-06-22

How to Cite

Sbidian, E., Mezzarobba, M., Shourick, J., Billionnet, C., Coste, J., Weill, A., … Nijsten, T. E. (2021). Choice of Systemic Drugs for the Management of Moderate-to-severe Psoriasis: A Cross-country Comparison Based on National Health Insurance Data. Acta Dermato-Venereologica, 101(6), adv00473. https://doi.org/10.2340/00015555-3765